Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081986 | 0.92 | HTT (0.52) | CACNA2D1ALDH1A1SMN1; SMN2GAAHTT | |
| SCHEMBL6082602 | 0.86 | CACNA2D1 (0.59) | CACNA2D1ALDH1A1TSHRHPGDSMN1; SMN2 | |
| SCHEMBL6026147 | 0.86 | CACNA2D1 (0.56) | CACNA2D1ALDH1A1TSHRHPGDSMN1; SMN2 | |
| SCHEMBL6082444 | 0.84 | CACNA2D1 (0.55) | CACNA2D1ALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL6082653 | 0.82 | CACNA2D1 (0.59) | CACNA2D1ALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL6025807 | 0.80 | CACNA2D1 (0.51) | CACNA2D1ALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL6082598 | 0.80 | CACNA2D1 (0.52) | CACNA2D1ALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL6026332 | 0.80 | CACNA2D1 (0.73) | CACNA2D1ALDH1A1TSHRSMN1; SMN2GAA | |
| SCHEMBL13982788 | 0.79 | CACNA2D1 (0.47) | CACNA2D1ALDH1A1TSHRSMN1; SMN2HTT | |
| SCHEMBL6082187 | 0.79 | CACNA2D1 (0.54) | CACNA2D1ALDH1A1TSHRSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060705-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2006-06-13 | — | — | US | claimed |
| EP-1444209-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040259826-A1 | Mitotic kinesin inhibitors | MERCK & CO., INC. | 2004-12-23 | — | — | US | claimed |
| EP-1444209-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-08-11 | — | — | EP | claimed |
| WO-2003039460-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-7060705-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1444209-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040259826-A1 | Mitotic kinesin inhibitors | MERCK & CO., INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1444209-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003039460-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259826-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | CACNA2D1 3967/4885ALDH1A1 2572/4885TSHR 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.